GlassScriptPhysician profile
David C Whitehead
NPI 1962403766
$3,832.05
in general payments reported to CMS, 2019-2025
24 companies · $379 in 2025
The $379 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $105 · 2021: $154 · 2022: $942 · 2023: $603 · 2024: $961 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,943.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,913.96 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Boston Scientific Corporation | $304.41 | 2019-2025 | Exalt Model D, General - Hemostasis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $209.00 | 2019-2024 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $180.58 | 2019-2024 | Ocaliva |
| Janssen Biotech, INC. | $159.70 | 2019-2024 | Stelara |
| Braintree Laboratories, INC. | $156.99 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.72 | 2019-2025 | Entyvio |
| Olympus America INC. | $127.03 | 2019-2025 | Visiglide, Disposable Emr Kit, Endoclot Phs |
| Ferring Pharmaceuticals INC. | $80.46 | 2019-2023 | Rebyota |
| Gilead Sciences, INC. | $70.51 | 2019-2022 | |
| Organon LLC | $54.70 | 2024 | |
| Aimmune Therapeutics, INC. | $44.64 | 2024 | |
| Pfizer INC. | $41.80 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $41.52 | 2024-2025 | Voquezna |
| Vivus LLC | $41.43 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $41.22 | 2019 | |
| Ironwood Pharmaceuticals, INC | $35.90 | 2022-2023 | Linzess |
| Celgene Corporation | $35.68 | 2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $35.48 | 2025 | Dupixent |
| Genzyme Corporation | $34.90 | 2025 | |
| Tempus Ai, INC | $24.70 | 2024 | Xt Cdx |
| Ardelyx, INC. | $23.18 | 2024 | Ibsrela |
| Romark Laboratories, Lc | $10.82 | 2019 | |
| Ambu INC. | $9.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Whitehead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.